Trials / Completed
CompletedNCT00261378
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation
Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISION V)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 212 (actual)
- Sponsor
- Boston Scientific Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the safety and efficacy of DC Bead™ delivered by intra-arterial embolisation for the treatment of Hepatocellular Carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Transarterialchemoembolisation (TACE) | |
| DEVICE | DC Bead with Doxorubicin |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2005-12-05
- Last updated
- 2021-07-21
Locations
17 sites across 4 countries: Austria, France, Germany, Switzerland
Source: ClinicalTrials.gov record NCT00261378. Inclusion in this directory is not an endorsement.